Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

NCT04678830 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus Disease 2019

Interventions

DRUG: Placebos
DRUG: Leronlimab (700mg)

Sponsor

CytoDyn, Inc.

Collaborators

[object Object]